Kinases, homology models, and high throughput docking

被引:109
作者
Diller, DJ [1 ]
Li, RX [1 ]
机构
[1] Pharmacopeia Inc, Princeton, NJ 08543 USA
关键词
D O I
10.1021/jm020503a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
With the many protein sequences coming from the genome sequencing projects, it is unlikely that we will ever have an atomic resolution structure of every relevant protein. With high throughput crystallography, however, we will soon have representative structures for the vast majority of protein families. Thus the drug discovery and design process will rely heavily on protein modeling to address issues such as designing combinatorial libraries for an entire class of targets and engineering genome-wide selectivity over a target class. In this study we assess the value of high throughput docking into homology models. To do this we dock a database of random compounds seeded with known inhibitors into homology models of six different kinases. In five of the six cases the known inhibitors were found to be enriched by factors of 4-5 in the top 5% of the overall scored and ranked compounds. Furthermore, in the same five cases the known inhibitors were found to be enriched by factors of 2-3 in the top 5% of the scored and ranked known kinase inhibitors, thus showing that the homology models can pick up some of the crucial selectivity information.
引用
收藏
页码:4638 / 4647
页数:10
相关论文
共 77 条
[1]  
*ACC INC, CER 2
[2]  
*ACC INC, CAT 4 5
[3]  
*ACC INC, INS 2000
[4]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[5]   Oncogenic kinase signalling [J].
Blume-Jensen, P ;
Hunter, T .
NATURE, 2001, 411 (6835) :355-365
[6]   1-substituted 4-aryl-5-pyridinylimidazoles: A new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency [J].
Boehm, JC ;
Smietana, JM ;
Sorenson, ME ;
Garigipati, RS ;
Gallagher, TF ;
Sheldrake, PL ;
Bradbeer, J ;
Badger, AM ;
Laydon, JT ;
Lee, JC ;
Hillegass, LM ;
Griswold, DE ;
Breton, JJ ;
ChabotFletcher, MC ;
Adams, JL .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (20) :3929-3937
[8]   New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis [J].
Bold, G ;
Altmann, KH ;
Frei, J ;
Lang, M ;
Manley, PW ;
Traxler, P ;
Wietfeld, B ;
Brüggen, J ;
Buchdunger, E ;
Cozens, R ;
Ferrari, S ;
Furet, P ;
Hofmann, F ;
Martiny-Baron, G ;
Mestan, J ;
Rösel, J ;
Sills, M ;
Stover, D ;
Acemoglu, F ;
Boss, E ;
Emmenegger, R ;
Lässer, L ;
Masso, E ;
Roth, R ;
Schlachter, C ;
Vetterli, W ;
Wyss, D ;
Wood, JM .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (12) :2310-2323
[9]   Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines:: Identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors [J].
Boschelli, DH ;
Wu, ZP ;
Klutchko, SR ;
Showalter, HDH ;
Hamby, JM ;
Lu, GH ;
Major, TC ;
Dahring, TK ;
Batley, B ;
Panek, RL ;
Keiser, J ;
Hartl, BG ;
Kraker, AJ ;
Klohs, WD ;
Roberts, BJ ;
Patmore, S ;
Elliott, WL ;
Steinkampf, R ;
Bradford, LA ;
Hallak, H ;
Doherty, AM .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (22) :4365-4377
[10]   Tyrosine kinase inhibitors .8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor [J].
Bridges, AJ ;
Zhou, H ;
Cody, DR ;
Rewcastle, GW ;
McMichael, A ;
Showalter, HDH ;
Fry, DW ;
Kraker, AJ ;
Denny, WA .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (01) :267-276